SUPPLEMENTAL TABLE 1. Japanese Society for Cancer of the Colon and Rectum classification of lymph node stations
Group
Large bowel lymph node coding
Superior mesenteric arterial (SMA) system Inferior mesenteric arterial (IMA) system
Pericolic Lymph nodes along the colon wall and arterial edge.
Lymph nodes along the colon wall, arterial edge, lowermost branch of the sigmoid artery, and superior rectal
artery.
Intermediate
Lymph nodes along the ileocolic artery, right colic artery, right branch of the middle colic artery, and left branch of
the middle colic artery.
Lymph nodes along the left colic artery, sigmoid artery, and IMA from the origin of the left colic artery to the
lowermost branch of the sigmoid artery.
Main
Lymph nodes at the origin of the ileocolic artery, and along the right colic artery, right branch of the middle colic artery, left branch of the middle colic artery, and middle
colic artery.
Lymph nodes along the inferior mesenteric artery from the origin of the IMA to that of the left colic artery.
SUPPLEMENTAL TABLE 2. Baseline characteristics
Characteristic
Patients
P-value CME (N = 220) NCME (N = 110)
Age (years), median (range) 68 (58 – 77) 73 (57 – 79) 0.083
Sex, N (%)
M 120 (54.5) 54 (49.1)
F 100 (45.5) 56 (50.9) 0.349
BMI (kg/m2), mean (SD) 23.6 (3.3) 23.6 (3.7) 0.946
BSA (m2), mean (SD) 1.7 (0.2) 1.7 (0.2) 0.636
Comorbidity, N (%)
Anemia 21 (9.5) 4 (3.6) 0.056
Cardiovascular disease 109 (49.5) 52 (47.3) 0.697
Cerebrovascular disease 17 (7.7) 12 (10.9) 0.336
Diabetes 35 (15.9) 19 (17.3) 0.752
Kidney disease 9 (4.1) 3 (2.7) 0.757
Pulmonary disease 15 (6.8) 3 (2.7) 0.123
Tumor location, N (%)
Ascending colon 87 (39.5) 32 (29.1) 0.066
Cecum 27 (12.3) 19 (17.3) 0.258
Descending colon 5 (2.3) 9 (8.2) 0.018*
Hepatic flexure 14 (6.4) 6 (5.4) 0.222
Sigmoid colon 71 (32.3) 42 (38.2) 0.274
Splenic flexure 6 (2.7) 0 (0.0) 0.184
Transverse colon 10 (4.5) 2 (1.8) 0.350
Tumor side, N (%)
Right 138 (62.7) 59 (53.6)
Left 82 (37.3) 51 (46.4) 0.112
UICC stage, N (%)
I 21 (9.5) 7 (6.4)
II 105 (47.8) 61 (55.4)
III 94 (42.7) 42 (38.2) 0.348
pT stage, N (%)
pT1–2 25 (11.4) 8 (7.3)
pT3–4 195 (88.6) 102 (92.7) 0.234
N stage, N (%)
N0 126 (57.3) 66 (60.0)
N+ 94 (42.7) 44 (40.0) 0.636
RAS mutational, N (%)
N 148 (74.4) 72 (72.0)
Y 51 (25.6) 28 (28.0) 0.661
MMR status, N (%)
P 166 (83.8) 82 (81.2)
D 32 (16.2) 19 (18.8) 0.564
Adjuvant chemotherapy, N (%)
Y 103 (46.8) 54 (49.1)
N 117 (53.2) 56 (50.9) 0.697
*P < 0.05
MMR status was tested through the method of immunohistochemistry to determine protein expression of MLH1, MSH2, MSH6, PMS2. MMR-deficient tumors show complete loss of expression of one or more protein. MMR-proficient tumors show complete expression the 4 protein.
Abbreviations: BMI, body mass index; BSA, body surface area; CME, complete mesocolic excision; CS, conventional surgery NCME, non-complete mesocolic excision; F, female; M, male; N, no; p, pathological; SD, standard deviation; UICC, Union for International Cancer Control; MMR, mismatch repair; D, deficient; P, proficient; Y, yes.